Family · Pharmaceutical analytical standards
Apremilast
An oral phosphodiesterase 4 (PDE4) inhibitor that raises cyclic AMP inside cells and dampens the production of inflammatory molecules: approved in the United States in 2014 for psoriatic arthritis and plaque psoriasis, and in 2019 for the oral ulcers of Behçet's disease. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was born as a thalidomide analogue, sharing its phthalimide ring; unlike thalidomide, however, it does not bind the protein cereblon, because it lacks the glutarimide ring.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
